| Periodo | Patrimonio netto | Var. |
| 2025 | 4.32 B USD | +5.49% |
| 2024 | 4.09 B USD | +9.55% |
| 2023 | 3.74 B USD | +21.11% |
| 2022 | 3.09 B USD | -22.18% |
| 2021 | 3.97 B USD | +8.35% |
| 2020 | 3.66 B USD | +17.64% |
| 2019 | 3.11 B USD | +12.82% |
| 2018 | 2.76 B USD | +1.63% |
| 2017 | 2.71 B USD | +44.52% |
| 2016 | 1.88 B USD | +10.02% |
| 2015 | 1.71 B USD | +24.45% |
| 2014 | 1.37 B USD | +5.84% |
| 2013 | 1.30 B USD | +15.54% |
| 2012 | 1.12 B USD | — |
Jazz Pharmaceuticals plc is a biopharmaceutical company dedicated to identifying, developing, and commercializing innovative medicines that address unmet medical needs in serious diseases. It maintains a diverse portfolio of marketed products targeting rare epilepsies such as with Epidiolex, sleep disorders including narcolepsy treatments like Xyrem and Xywav, and various cancers through therapies like Zepzelca, Vyxeos, and Ziihera for specific indications including metastatic small cell lung cancer and HER2-positive biliary tract cancer. The company also offers treatments for rare diseases, hematology, and neuroscience conditions, supported by a robust pipeline of therapeutics. Jazz Pharmaceuticals plc operates globally with a patient-focused, science-driven approach, advancing research in oncology, neurology, and rare disease areas to transform patient lives. Founded in 2003 and headquartered in Dublin, Ireland, it plays a significant role in the biopharmaceutical market by providing specialized therapies where treatment options are limited.